+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neglected Tropical Disease Treatment Market - Global Forecast 2026-2032- Product Image
Neglected Tropical Disease Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Neglected Tropical Disease Treatment Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674161
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neglected Tropical Disease Treatment Market is projected to reach USD 4.47 Billion in 2026. It is expected to continue growing at a CAGR of 5.92%, reaching USD 6.34 Billion by 2032.

Neglected tropical disease treatment is moving from donation-led mass drug administration toward integrated, data-driven disease control that combines medicines, diagnostics, vector management, surveillance, and community delivery. The treatment landscape is shaped by the World Health Organization road map for 2021-2030, which targets a 90% reduction in people requiring NTD interventions and the elimination of at least one neglected tropical disease in 100 countries.

Demand remains significant because more than 1 billion people are affected by NTDs, with the highest burden in low-resource tropical and subtropical settings. Growth opportunities are concentrated in scalable antiparasitic therapies, point-of-care diagnostics, pediatric formulations, digital adherence tools, and partnerships that align public health outcomes with sustainable access models.

Transformative Shifts in the NTD Treatment Landscape

The neglected tropical disease treatment landscape is being reshaped by integrated disease programs, stronger pharmacovigilance, and a shift from campaign-based interventions to continuous surveillance. Countries are increasingly combining lymphatic filariasis, onchocerciasis, soil-transmitted helminthiasis, schistosomiasis, trachoma, Chagas disease, leishmaniasis, and dengue strategies with primary care and community health systems.

Transformative momentum is also coming from fixed-dose combinations, shorter treatment regimens, vector-control innovation, and expanded regulatory pathways for priority medicines. Donor-funded access remains vital, but procurement decisions are becoming more evidence based, with ministries and global health agencies prioritizing treatments that demonstrate safety, operational simplicity, resistance monitoring, and measurable progress toward elimination targets.

Cumulative Impact of Artificial Intelligence on NTD Treatment

Artificial intelligence is creating cumulative value across neglected tropical disease treatment by improving risk mapping, diagnosis, trial design, and medicine distribution. Machine learning models using climate, mobility, vector, and case-reporting data can help identify hotspots for dengue, schistosomiasis, leishmaniasis, and other diseases where transmission changes with rainfall, temperature, urbanization, and population movement.

AI-enabled image analysis is strengthening microscopy, lesion recognition, and field diagnostics, while predictive analytics can reduce stockouts during mass drug administration campaigns. The highest-impact use cases are those validated in local health systems, governed by transparent data standards, and paired with human expertise to avoid bias in underserved populations.

Key Regional Insights Across NTD Treatment Markets

Asia-Pacific remains central to NTD treatment because of large at-risk populations, strong public health campaigns, and continuing burdens from dengue, soil-transmitted helminths, lymphatic filariasis, schistosomiasis, and leprosy in selected settings. The region benefits from large-scale deworming initiatives, school-based delivery, and expanding laboratory capacity, while island and border areas continue to require sustained surveillance. North America contributes through public health expertise, federally supported research, diagnostics innovation, and procurement influence, while also managing imported cases and rising vector-borne disease risk in warmer regions.

Latin America is a priority region for Chagas disease, leishmaniasis, dengue, and soil-transmitted helminth control, with established vector-control programs and national surveillance systems supporting treatment access. Europe is important for funding, regulatory science, tropical medicine research, and management of travel-associated and migration-linked infections. The Middle East faces risk from cutaneous leishmaniasis, dengue emergence, and population mobility, making surveillance and migrant health services increasingly relevant. Africa carries the largest NTD burden and remains the core region for mass drug administration, elimination programs, community-directed treatment, and integrated control of lymphatic filariasis, onchocerciasis, schistosomiasis, trachoma, and soil-transmitted helminthiasis.

Key Group Insights for NTD Treatment Strategy

ASEAN countries are advancing NTD control through dengue programs, deworming campaigns, lymphatic filariasis elimination, and cross-border surveillance, making the bloc important for scalable community delivery and vector-control innovation. GCC countries are less burdened by endemic NTDs than tropical regions but play a growing role in travel health, migrant health screening, humanitarian financing, and surveillance for dengue and leishmaniasis, particularly as mobility, urbanization, and climate suitability shift regional risk patterns.

The European Union supports neglected tropical disease treatment through health research funding, regulatory harmonization, and global health programs that strengthen diagnostics, medicines development, and implementation science. BRICS countries combine high disease burden, manufacturing scale, and expanding clinical research capacity, particularly across Brazil, India, China, and South Africa. G7 members remain pivotal funders of research, procurement, and access initiatives, while NATO countries indirectly influence preparedness through humanitarian logistics, biosecurity cooperation, emergency response planning, and health-system resilience relevant to outbreak-prone and climate-sensitive NTDs.

Key Country Insights Shaping NTD Treatment Demand

The United States leads in NTD research funding, public health guidance, diagnostics development, and drug discovery partnerships, while Canada contributes through global health financing, surveillance expertise, and academic tropical medicine programs. Mexico and Brazil remain essential Latin American markets because of dengue, Chagas disease, leishmaniasis, and vector-control priorities, with Brazil also holding significant expertise in arboviral disease management and public-sector treatment delivery. The United Kingdom, Germany, and France are influential in clinical research, donor funding, regulatory science, pharmacovigilance, and public-private partnerships for access.

Russia, Italy, and Spain are relevant for surveillance, travel medicine, and imported or climate-sensitive vector-borne disease risk, particularly as Aedes mosquito distribution and heat-related transmission suitability change across parts of Europe. China has made major progress against schistosomiasis and has broad pharmaceutical manufacturing and diagnostics capacity. India carries one of the largest NTD treatment needs, especially for lymphatic filariasis, visceral leishmaniasis, soil-transmitted helminths, leprosy, and dengue, supported by national elimination programs and large-scale community health infrastructure. Japan, Australia, and South Korea add value through innovation, regional health security, diagnostics, development assistance, and Indo-Pacific surveillance partnerships.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize affordable formulations, heat-stable products, pediatric dosing, and simplified regimens that fit community health delivery. Partnerships with ministries of health, WHO-aligned programs, NGOs, academic centers, and local manufacturers can improve access while supporting sustainable demand generation and regulatory acceptance.

Organizations should also invest in field-ready diagnostics, AI-supported surveillance, pharmacovigilance, and evidence packages that demonstrate cost-effectiveness, safety, adherence, and impact on elimination goals. The strongest competitive positions will come from combining product innovation with implementation support, local capacity building, resistance monitoring, supply-chain resilience, and transparent access commitments.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in publicly available data from the World Health Organization, national public health agencies, peer-reviewed literature, clinical trial registries, regulatory sources, and recognized global health organizations. Interpretation is aligned with WHO NTD road map priorities, disease-burden patterns, treatment guidelines, medicine donation frameworks, and procurement dynamics.

Insights are triangulated across epidemiology, policy, funding, pipeline activity, regional disease prevalence, access initiatives, and technology adoption indicators. Findings are validated for consistency across sources and framed to support strategic planning, competitive assessment, and opportunity prioritization in neglected tropical disease treatment without relying on market sizing, market share, or forecasting assumptions.

Conclusion

Neglected tropical disease treatment is entering a more integrated and technology-enabled phase, with elimination goals, AI-supported surveillance, improved diagnostics, and resilient medicine access shaping strategic direction. The sector remains defined by high unmet need, public health urgency, and the need for affordable products that perform reliably in low-resource environments.

Organizations that align innovation with community delivery, evidence-based procurement, and regional elimination priorities will be best positioned to create measurable health impact. The long-term opportunity lies in closing access gaps while building sustainable systems for detection, treatment, monitoring, prevention, and equitable care delivery.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Neglected Tropical Disease Treatment Market, by Drug Type
7.1. Introduction
7.2. Drug therapy
7.2.1. Antiparasitics
7.2.2. Antibacterials
7.2.3. Antivirals
7.2.4. Antifungals
7.3. Biologics & Immunotherapy
7.3.1. Therapeutic Vaccines
7.3.2. Monoclonal Antibodies
7.4. Surgical/Procedural interventions
8. Neglected Tropical Disease Treatment Market, by Route Of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
8.3.1. Intramuscular
8.3.2. Intravenous
8.3.3. Subcutaneous
8.4. Topical
9. Neglected Tropical Disease Treatment Market, by Treatment Approach
9.1. Introduction
9.2. Mass Drug Administration
9.3. Targeted Therapy
10. Neglected Tropical Disease Treatment Market, by Disease Indication
10.1. Introduction
10.2. Viral NTDs
10.2.1. Dengue
10.2.2. Chikungunya
10.2.3. Rabies
10.3. Bacterial NTDs
10.3.1. Buruli Ulcer
10.3.2. Trachoma
10.3.3. Yaws
10.4. Parasitic NTDs
10.4.1. Protozoan Infections
10.4.2. Helminthic Infections
10.5. Fungal NTDs
11. Neglected Tropical Disease Treatment Market, by Patient Age group
11.1. Introduction
11.2. Pediatric
11.3. Adult
11.4. Geriatic
12. Neglected Tropical Disease Treatment Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Community Health Centers
12.4. Hospitals
12.5. Research Institutes & Clinical Trial Sites
13. Neglected Tropical Disease Treatment Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Neglected Tropical Disease Treatment Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Neglected Tropical Disease Treatment Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Astellas Pharma Inc.
17.3. AstraZeneca plc
17.4. Bayer AG
17.5. Boehringer Ingelheim International GmbH
17.6. Bristol Myers Squibb Company
17.7. Cipla Limited
17.8. Daiichi Sankyo Company, Limited
17.9. Eiken Chemical Co., Ltd.
17.10. Eisai Co., Ltd.
17.11. Eli Lilly and Company
17.12. EMS S.A.
17.13. F. Hoffmann-La Roche Ltd
17.14. Gilead Sciences, Inc.
17.15. GlaxoSmithKline plc
17.16. Johnson & Johnson
17.17. Merck & Co., Inc.
17.18. Merck KGaA
17.19. Novartis AG
17.20. Novo Nordisk A/S
17.21. Pfizer Inc.
17.22. Sanofi S.A.
17.23. Shionogi & Co., Ltd.
17.24. Sinopharm Group Co. Ltd.
17.25. Takeda Pharmaceutical Company Limited
17.26. Teva Pharmaceutical Industries Ltd.
17.27. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL DRUG THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL DRUG THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL DRUG THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ANTIPARASITICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ANTIPARASITICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ANTIPARASITICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ANTIBACTERIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ANTIBACTERIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ANTIBACTERIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS & IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS & IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS & IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SURGICAL/PROCEDURAL INTERVENTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SURGICAL/PROCEDURAL INTERVENTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SURGICAL/PROCEDURAL INTERVENTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL MASS DRUG ADMINISTRATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL MASS DRUG ADMINISTRATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL MASS DRUG ADMINISTRATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL VIRAL NTDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL VIRAL NTDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL VIRAL NTDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL DENGUE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL DENGUE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL DENGUE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CHIKUNGUNYA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CHIKUNGUNYA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CHIKUNGUNYA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL RABIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL RABIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL RABIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL BACTERIAL NTDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL BACTERIAL NTDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL BACTERIAL NTDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL BURULI ULCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL BURULI ULCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL BURULI ULCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL TRACHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL TRACHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL TRACHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL YAWS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL YAWS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL YAWS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL PARASITIC NTDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL PARASITIC NTDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL PARASITIC NTDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL PROTOZOAN INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL PROTOZOAN INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL PROTOZOAN INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HELMINTHIC INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HELMINTHIC INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HELMINTHIC INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL FUNGAL NTDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL FUNGAL NTDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL FUNGAL NTDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL GERIATIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL GERIATIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL GERIATIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL RESEARCH INSTITUTES & CLINICAL TRIAL SITES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL RESEARCH INSTITUTES & CLINICAL TRIAL SITES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL RESEARCH INSTITUTES & CLINICAL TRIAL SITES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 133. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 134. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 135. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 136. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 137. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 138. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 139. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 140. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 141. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 142. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 143. EUROPE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 170. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 171. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 172. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 173. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 174. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 175. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 176. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 177. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 178. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 179. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 180. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 181. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 182. AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 192. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 194. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 197. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 198. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 199. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 200. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 201. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 202. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 203. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 204. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 205. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 206. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 207. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 208. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 209. NATO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 210. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 211. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 212. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 213. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 214. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 216. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 217. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 218. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 219. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 220. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 221. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 222. G7 NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 224. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 225. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 226. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 227. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 228. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 229. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 230. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 231. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 232. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 233. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 234. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 235. BRICS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 250. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 251. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 252. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 253. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 254. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 255. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 256. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 257. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 258. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 259. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 260. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 261. ASEAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 263. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 264. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 265. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 266. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 267. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 268. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 269. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 270. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 271. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 272. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 273. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 274. GCC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 275. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 276. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 277. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 278. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 279. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 280. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 281. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 282. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 283. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 284. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 285. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 286. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 287. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 288. CHINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 291. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 292. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 293. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 294. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 295. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 297. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 298. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 299. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 300. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 301. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 304. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 305. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 306. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 307. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 308. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 309. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 310. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MILLION)
TABLE 311. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BACTERIAL NTDS, 2017-2032 (USD MILLION)
TABLE 312. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARASITIC NTDS, 2017-2032 (USD MILLION)
TABLE 313. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 314. JAPAN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 315. INDIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. INDIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 317. INDIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 318. INDIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS & IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 319. INDIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 320. INDIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 321. INDIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2017-2032 (USD MILLION)
TABLE 322. INDIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 323. INDIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY VIRAL NTDS, 2017-2032 (USD MIL

Companies Mentioned

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • Eiken Chemical Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • EMS S.A.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Shionogi & Co., Ltd.
  • Sinopharm Group Co. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.47 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.34 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Neglected Tropical Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Neglected Tropical Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Neglected Tropical Disease Treatment Market Size, Share & Trends Analysis Report by Disease (Dengue, Rabies, Trachoma, Chagas Disease), by Product (Drugs, Vaccines), by Region, and Segment Forecasts, 2025-2033 - Product Image

Neglected Tropical Disease Treatment Market Size, Share & Trends Analysis Report by Disease (Dengue, Rabies, Trachoma, Chagas Disease), by Product (Drugs, Vaccines), by Region, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
Neglected Tropical Disease Treatment Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Neglected Tropical Disease Treatment Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 90 Pages
  • Global
From
Neglected Tropical Disease Treatment - Global Strategic Business Report - Product Image

Neglected Tropical Disease Treatment - Global Strategic Business Report

  • Report
  • 294 Pages
  • Global
From
Neglected Tropical Disease Treatment Market Report 2026 - Product Image

Neglected Tropical Disease Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.